Novogenia AG, Munich

Novogenia is a European market leader in lifestyle genetic diagnostics and a worldwide pioneer in preventive genetic diagnostics. We test human gene samples for the probability of disease, as well as for lifestyle advice, such as weight management nutrition, which vary for each person. Every month, Novogenia takes in more than 50,000 samples and analyses them fully automated under the tight regulations of the Austrian Law of Genetic Technology.

One of our favorites is our “Baby 100” test, where we extract 250 different metabolic products from a paper pad that has been sprinkled with your baby’s urine. As a result, over 100 different rare diseases can be detected and, if prevalent, treated. These diseases have the following vital characteristics: Firstly, they are very rare, therefore unlikely to be spotted by a pediatrician; secondly, they are extremely harmful and can even lead to a baby’s death; Thirdly, with our test, however, they can be spotted and usually treated rather easily, resulting in normal development of the child.

Another example is hemochromatosis (iron deficiency), a frequent genetic disorder that can lead to impaired joints, cause diabetes, and damage the liver. If this disorder is spotted before the disease breaks out (usually 50+), you simply must donate blood 4-6 times a year and nothing happens at all.

Another product line are cosmetics (skin cremes), which are custom mixed and bottled to each customer’s genetic profile.

Since the start of the COVID-pandemic in 2020, we have dedicated a part of our lab capacities to PCR-analyses for the detection of the SARS virus in salvia.

In October 2021, Novogenia listed in the Open Market of the Munich stock exchange. DVM holds about 25% of the shares of Novogenia Holding AG, Munich, which is 100% owner of the operative lab Novogenia GmbH in Eugendorf near Salzburg.